15th Nov 2016 10:43
LONDON (Alliance News) - Silence Therapeutics PLC Tuesday said it will present "significant" data demonstrating the potential of its delivery platform for in vivo gene editing at the EuroTIDES 2016 conference in Berlin, Germany.
Silence Therapeutics is developing ribonucleic acid-based technologies that can be used to selectively silence or replace any gene in a genome. The data being presented relates to a proof of concept study of the use of Silence's targeted lipid nanoparticle to deliver CRISPR/Cas9 gene editing components.
"As in RNA interference, efficient payload delivery is critical in gene editing. We have leveraged our experience in RNA delivery systems to demonstrate that our lipid nanoparticle can be used for CRISPR/Cas9 applications," said Chief Executive Officer Ali Mortazavi in a statement.
"We have shown that our LNPs are suitable for the delivery of large cargos such as RNA CRISPR/Cas9 components, and we are discussing collaborations in this area with potential partners," Mortazavi added.
Shares in Silence Therapeutics were flat at 113.50 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L